Which gene SNPs are analysed?
Current evidence indicates several areas in which genetic testing is of proven clinical benefit.
- Cardiovascular disease
Cardiovascular diseases (CVD) are the leading cause of death in developed countries.
Classic risk factors, such as obesity, diabetes, hypertension, lipid profile, poor diet, alcohol consumption, smoking habits, lack of exercise and stress play an important role in coronary heart disease. Recent studies however show that besides physiological and behavioural risk factors, the individual genetic predisposition significantly contributes to the development of CVD. Our cardiovascular SNP profile analyses the individual genomic constellation with regard to personal risk factors in connection with CVD. The knowledge of the personal genomic constellation of a patient helps the physician to select suitable primary preventive therapeutic measures as well as to plan individual medication in order to avoid or reduce specific risks of developing CVD.
The CardioSensor Premium test covers polymorphisms that are associated with the following cardiovascular risk fields:
- arteriosclerosis and lipid metabolism
- homeostasis of blood clotting (thrombosis)
- metabolism and obesity
back to top
The genetic predisposition to a number of cancers is now recognised. Our profiles analyse some of the most important SNPs that have been shown to play a role in cancer risk.
back to top
In addition to “prostate cancer–specific polymorphisms” the AndroSensor 40plus covers other polymorphisms that are associated with the genetic influence on:
- chronic inflammation
- lipid metabolism and stroke risk
- disordered detoxification
- testosterone bio-activity and metabolism
back to top
PharmacoSensor Individual Drug Metabolism
Impaired drug metabolism is a major cause of adverse drug reactions (ADRs). Drug metabolism may be impaired if variations in genes that code for drug-metabolizing enzymes are present. Such genetic variations may lead to ADRs such as reduced drug efficacy and/or increased drug toxicity.
Thus, detection of genetic variants related to drug metabolizing enzymes may be useful for predicting or explaining an ADR.
The primary use for CYP2D6, CYP2C9 and CYP2C19 gene analysis is to identify individuals who possess variant alleles. This information may be used to guide drug and dose selection for individuals, with the ultimate goal of predicting the patients’ responses to medication and/or propensity to develop drug-associated toxicity. Specific changes to drug regimens and/or dosing based on genotype results should be determined for the individual clinical situation .
Depending on their genetic profiles, people can be assigned to metabolizer-groups:
- Extensive Metabolizer (EM; normal enzyme activity)
- Intermediate Metabolizer (IM; reduced enzyme activity)
- Poor Metabolizer (PM; no enzyme activity)
Some selected examples of drugs metabolised by CYP2D6, CYP2C9 and CYP2C19 are:
Amitriptylin, Codein, Desipramine, Dextromethorphan, Flecainide, Fluoxetine, Haloperidol, Metoprolol, Nortriptyline, Paroxetine, Propafenone, Timolol, Tramadol, Venlafaxin
Celecoxib, Diclofenac, Glipizide, Ibuprofen, Indomethacin, Irbesartan, Losartan,
Meloxicam, Naproxen, Phenytoin, Piroxicam, Tolbutamide, S-Warfarin
Citalopram, Diazepam, Flunitrazepam, Lansoprazole, Omeprazole, Pantoprazole,
back to top
For further information please